Predictors of mortality in alpha1-antitrypsin deficiency - Wikidata - wikimedia - TriplyDB

Predictors of mortality in alpha1-antitrypsin deficiency

Predictors of mortality in alpha1-antitrypsin deficiency

http://www.wikidata.org/entity/Q35535625

about

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences Rationale and design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis. Alpha-1 protocol Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline Air pollution and percent emphysema identified by computed tomography in the Multi-Ethnic study of Atherosclerosis.Association between emphysema-like lung on cardiac computed tomography and mortality in persons without airflow obstruction: a cohort study BODE-Index vs HADO-score in chronic obstructive pulmonary disease: Which one to use in general practice?Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.A combined pulmonary function and emphysema score prognostic index for staging in Chronic Obstructive Pulmonary Disease α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.Racial differences in CT phenotypes in COPD.Alpha1-antitrypsin deficiency. 7: Computed tomographic imaging in alpha1-antitrypsin deficiency.Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances.Imaging in chronic obstructive pulmonary disease.New insights on COPD imaging via CT and MRI.Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study Predictors of mortality in patients with emphysema and severe airflow obstruction.Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?The effect of α1-antitrypsin deficiency combined with increased bacterial loads on chronic obstructive pulmonary disease pharmacotherapy: A prospective, parallel, controlled pilot study alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies.Sex-specific features of emphysema among current and former smokers with COPD.Emerging drugs for alpha-1-antitrypsin deficiency.The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency.Alpha-1 antitrypsin deficiency: the European experience.The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with COPD.Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life.Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.Lung Transplantation in Alpha-1-Antitrypsin Deficiency.Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments.Mortality by level of emphysema and airway wall thickness.Lung densitometry: why, how and when.Normalized emphysema scores on low dose CT: Validation as an imaging biomarker for mortality.The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency.Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy.Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment.

P2860

Q21202920-BA0E275A-4877-4EAE-8D75-3EC1F6CA7398 Q23911017-EC4E11B4-88FC-49AE-9E42-B07708D4138A Q28385458-C1111AFC-924D-4AC8-A79C-5F8DC9E42B2C Q28387179-68E32587-2273-4689-838F-DF3C7C3659EA Q28389082-E98B6CE0-DB59-4E9B-A099-C95731ECD1FF Q33585772-4C777F5E-8B87-4CC6-B104-C34FE983CBD5 Q33743024-8D951CD8-2A1D-4CD1-A9D4-171B5EDC7952 Q34243582-C83E8B02-51F9-4228-9B4E-C2BF7AD4FB4E Q34400702-3A07E69D-B05A-4DDF-B0A8-D0464EFC3618 Q34428735-14CE0232-2AF2-4A02-B883-76E02C141CAD Q34778477-16B5A60C-A252-4338-9B71-5FFC31A34CE6 Q35064411-AD777D8C-AEFC-40E7-A55B-120F544DB3C7 Q35536338-E223886F-FF9A-45B9-9E4B-B13F8714A69F Q36203151-2B1934FD-EAB7-4D2C-8972-9D1567184091 Q36444197-DCCC57FB-2EA4-4C77-B924-FC384A5C0A7C Q36526956-0D12DD58-EB00-4030-B328-8A16E54869C3 Q36832380-90A448C3-9065-4457-82AD-F8289C043AF2 Q37071025-7137A6B9-2910-4290-8463-333E3F8DC992 Q37125913-46A3A10E-FC29-41F7-9D31-5F89FB5E42F4 Q37144509-DE806DA0-9668-4D7D-8C83-B1A8E7E09CC3 Q37158517-4400CD0A-DA0C-42E2-A12F-E53F788AFBA0 Q37410088-F78AD0AE-AD67-4DC9-B924-7F6F9D007DF9 Q37474870-C2D964CF-5F95-4A0C-B763-B166911740FD Q37731740-38DF7B53-4E74-4128-B484-91896D49A893 Q37780552-BCC2E64C-36BD-4CAD-BBF1-6DF3AE856604 Q37894093-B17CC54B-C4D3-4143-B0EC-F6328AD4C9EB Q38092880-2BDB6918-9CD7-4DED-9A84-7A9D229D24B2 Q38604630-2F81B0CB-A246-4A79-AAD2-AD5B65C3DDFE Q38832928-CAD016C4-425A-47B0-BCC0-160F3924FF02 Q39404790-6602B0E3-3C8B-43C1-8D0E-539DB26DD019 Q39450745-DC0E0146-751D-47C0-9460-5FFD1B2CE819 Q41138327-28410A78-16F1-45F6-9DCC-96E0B93F83EB Q41197170-4FB850C0-D5C9-4A67-B792-E99F5514338F Q42868217-F1A7FB94-FF7B-4715-87A5-8803B5EF4FEB Q43645727-34D6A656-39D5-48A0-9356-7660556D6FEB Q47163543-BAB250DA-7F91-49A1-9BD6-8752BE8B5632 Q47330724-1D4755D8-E241-4507-BA1D-2CC53AF6CD2F Q47659859-CF95B477-5687-427D-917F-C0919FCB98FE Q47703811-568187AE-4F78-4123-B2EB-448BC8C1D276 Q47943424-84AD2055-1289-46FD-A611-BF8C1B89549E

P2860

Predictors of mortality in alpha1-antitrypsin deficiency

http://www.wikidata.org/entity/Q35535625

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Predictors of mortality in alpha1-antitrypsin deficiency

@ast

Predictors of mortality in alpha1-antitrypsin deficiency

@en

type

label

Predictors of mortality in alpha1-antitrypsin deficiency

@ast

Predictors of mortality in alpha1-antitrypsin deficiency

@en

prefLabel

Predictors of mortality in alpha1-antitrypsin deficiency

@ast

Predictors of mortality in alpha1-antitrypsin deficiency

@en

P1433

Q35535625-A93477D9-2819-4501-A38F-1D430DCE67C0

P1476

Q35535625-9909A0E0-C44A-45DE-848F-B0C5E939C0F0

P2093

Q35535625-376B8331-2D80-4D95-BA1A-BF3E9DEA421A

Q35535625-8EA74698-742A-4D07-B544-91C37530C4B2

Q35535625-AA23218F-EC9A-4E03-A61E-B97B4BC545D6

Q35535625-DFAAD212-BC82-4819-9D55-941239ADDD7C

P2860

Q35535625-09B59926-5F49-4EE1-B16F-E5C1C46E7FDA

Q35535625-11FF6AE6-4973-4C81-BC5D-C8C71F7CBFE7

Q35535625-125DF67D-08F9-4778-BCC4-D4C803D7C6B7

Q35535625-13A7A962-9743-4617-895A-1F7F24DF8ACD

Q35535625-17416716-40E2-40EB-9583-05E97CF44BED

Q35535625-1EA403FF-A7F9-4ECD-8F3E-B468D314E40F

Q35535625-269D4A3B-FF36-4EFB-8FF7-9223B71C80C8

Q35535625-30399A23-82B2-426A-B194-DF5DC3B6775E

Q35535625-3EDFA27C-ECCA-4170-B767-41EA5F6A323E

Q35535625-40C73146-0163-4331-8550-D0F3F3574555

P304

Q35535625-5F973628-49E9-44AB-AC0B-79F5D28F84F7

P31

Q35535625-A717A3D9-05FE-44C3-9854-2334CA13BE5A

P356

Q35535625-F0C21CA0-F57F-4F11-85B7-B9B3CA285AB9

P407

Q35535625-C5A61EA3-3E1C-4C21-9690-B4962F150F1E

P433

Q35535625-3AC49A0B-9C3B-4300-8001-288D21F1CC8A

P478

Q35535625-07D3E85C-66F4-4F22-BEE7-D036BEB7E3BB

P577

Q35535625-180DBD57-D991-413C-9A3E-5FCB43CE520A

P698

Q35535625-A71442AA-FB7F-4FF9-9392-0BBCCD502AEE

P932

Q35535625-537BBAF4-0F65-41BF-AE42-530E0E05B143

P356

THORAX.58.12.1020

P1433

P1476

Predictors of mortality in alpha1-antitrypsin deficiency

@en

P2093

Dawkins PA

http://www.w3.org/2001/XMLSchema#string

Dowson LJ

http://www.w3.org/2001/XMLSchema#string

Guest PJ

http://www.w3.org/2001/XMLSchema#string

Stockley RA

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

The natural history of chronic airflow obstruction

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Quantitative computed tomography assessment of lung structure and function in pulmonary emphysema.

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force.

Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.

A population based case-control study of cataract and inhaled corticosteroids.

Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease.

Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.

Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study.

P304

1020-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THORAX.58.12.1020

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14645964

http://www.w3.org/2001/XMLSchema#string

P932

1746543

http://www.w3.org/2001/XMLSchema#string